A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT ID: NCT06948422
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
974 participants
INTERVENTIONAL
2025-04-30
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT05872620
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orforglipron (GZL1)
Participants will receive orforglipron orally or placebo.
Orforglipron
Administered orally.
Placebo
Administered orally.
Orforglipron (GZL2)
Participants will receive orforglipron orally or placebo.
Orforglipron
Administered orally.
Placebo
Administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orforglipron
Administered orally.
Placebo
Administered orally.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at week 0 (Visit 3).
* Untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to Visit 1.
* Have a body mass index (BMI) ≥ 25 kg/m².
Exclusion Criteria
* Has known secondary causes of hypertension
* Have heart failure with reduced ejection fraction (HFrEF) diagnosis
* Have had any of the following conditions within 90 days prior to screening.
* hospitalization for hypertension or for congestive heart failure
* acute coronary syndrome or acute myocardial infarction, or
* cerebrovascular accident (stroke).
* Have type 1 diabetes (T1D)
* Have acute or chronic hepatitis, including a history of autoimmune hepatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Elite Clinical Studies, LLC
Phoenix, Arizona, United States
Valley Clinical Trials, Inc.
Covina, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Excel Medical Clinical Trials
Boca Raton, Florida, United States
Care Access - Brandon
Brandon, Florida, United States
Northeast Research Institute - Downtown Office
Jacksonville, Florida, United States
Peace River Cardiovascular Center
Port Charlotte, Florida, United States
Care Access - St. Petersburg
St. Petersburg, Florida, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Sinai Hospital Of Baltimore
Baltimore, Maryland, United States
Ascension Saint Agnes Heart Care
Baltimore, Maryland, United States
Lucida Clinical Trials
New Bedford, Massachusetts, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Excel Clinical Research, LLC
Las Vegas, Nevada, United States
Palm Research Center Sunset
Las Vegas, Nevada, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
Remington-Davis, Inc
Columbus, Ohio, United States
PriMED Clinical Research
Dayton, Ohio, United States
Advanced Research Institute - Tigard
Tigard, Oregon, United States
Care Access - Mauldin
Mauldin, South Carolina, United States
Dallas Heart and Vascular Consultants, PA
Duncanville, Texas, United States
Texas Institute of Cardiology, PA
McKinney, Texas, United States
North Hills Family Medicine/North Hills Medical Research
North Richland Hills, Texas, United States
Advanced Research Institute
Ogden, Utah, United States
Carient Heart & Vascular - Manassas
Manassas, Virginia, United States
Health Research of Hampton Roads, Inc.
Newport News, Virginia, United States
National Clinical Research, Inc
Richmond, Virginia, United States
Eastside Research Associates
Redmond, Washington, United States
Instituto Médico Especializado (IME)
Buenos Aires, , Argentina
CIPREC
Buenos Aires, , Argentina
CIPREC
Buenos Aires, , Argentina
CEMEDIC
Buenos Aires, , Argentina
Instituto de Investigaciones Clínicas Córdoba
Córdoba, , Argentina
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, , Argentina
INECO Neurociencias Oroño
Rosario, , Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
Rosario, , Argentina
Santa Maria de la Salud Centro Medico
San Isidro, , Argentina
Beijing Pinggu District Hospital
Beijing, , China
China-Japan Union Hospital
Changchun, , China
Changde First People's Hospital
Changde, , China
Sichuan Provincial People's Hospital
Chengdu, , China
The Second Affiliated Hospital of Chongqing Medical University - Yuzhong Campus
Chongqing, , China
Jinan Central Hospital
Jinan, , China
Lishui Central Hospital
Lishui, , China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, , China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, , China
Siping Central People's Hospital
Siping, , China
Wuxi People's Hospital
Wuxi, , China
Shaanxi provincial people's hospital
Xi'an, , China
Top Moravia Health
Brno, , Czechia
Ordinace Rihackovi, s.r.o.
Brno, , Czechia
CTC Hodonin s.r.o.
Hodonín, , Czechia
MUDr. Sarka Drinkova
Ledeč nad Sázavou, , Czechia
CCR Ostrava s.r.o
Ostrava, , Czechia
Diahelp s.r.o
Pardubice V, , Czechia
Clinoxus
Prague, , Czechia
Angiocentrum Komorany
Prague, , Czechia
Praglandia s.r.o
Prague, , Czechia
Zentrum für klinische Studien Bad Homburg
Bad Homburg, , Germany
FutureMeds GmbH
Berlin, , Germany
Zentrum fur klinische Forschung - Köln
Cologne, , Germany
Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien
Dresden, , Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Medizentrum Essen Borbeck
Essen, , Germany
AmBeNet GmbH
Leipzig, , Germany
Familienmedizinisches Zentrum Radowsky
Leipzig, , Germany
RED-Institut GmbH
Oldenburg, , Germany
Athens Medical Center - Psychikon branch
Athens, , Greece
General Hospital of Athens "G. Gennimatas"
Athens, , Greece
University Hospital of Ioannina
Ioannina, , Greece
G. Gennimatas General Hospital of Thessaloniki
Thessaloniki, , Greece
AHEPA University General Hospital of Thessaloniki
Thessaloniki, , Greece
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, , Greece
Life Care Hospital and Research Centre
Bangalore, , India
All India Institute of Medical Sciences
Bhubaneswar, , India
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, , India
Ashirwad Hospital and Research Centre
Ulhasnagar, , India
Tokyo-Eki Center-building Clinic
Chūōku, , Japan
Fukuwa Clinic
Chūōku, , Japan
Takai Internal Medicine Clinic
Kamakura-shi, , Japan
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, , Japan
Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
Yamato-shi, , Japan
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, , Poland
Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk
Bydgoszcz, , Poland
NZOZ Centrum Medyczne KERmed
Bydgoszcz, , Poland
IRMED
Piotrkow Trybunalski, , Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu
Przemyśl, , Poland
Private Practice - Dr. Robert Witek
Tarnów, , Poland
Balsam Medica
Warsaw, , Poland
NZOZ Regionalna Poradnia Diabetologiczna
Wroclaw, , Poland
Dorado Medical Complex
Dorado, , Puerto Rico
Puerto Rico Medical Research
Ponce, , Puerto Rico
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, , Spain
Hospital San Rafael - La Coruña
A Coruña, , Spain
EAP Sardenya
Barcelona, , Spain
EAP Osona Sud - Alt Congost S.L.P
Centelles, , Spain
Complejo Asistencial Universitario de León - Hospital de León
León, , Spain
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, , Spain
Hospital Quiron Infanta Luisa
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2A-MC-GZPL
Identifier Type: OTHER
Identifier Source: secondary_id
J2A-MC-GZL1
Identifier Type: OTHER
Identifier Source: secondary_id
J2A-MC-GZL2
Identifier Type: OTHER
Identifier Source: secondary_id
27223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.